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INTRODUCTION
Pituitary adenomas are generally benign tumor, and
the majority of pituitary adenomas do not metastasize
to distance sites, but about 30% of them invade to
the local tissues, such as cavernous sinus, sphenoid
sinus, orbit and clivus (1-4). The radical surgical treat-
ment of the invasive pituitary adenoma ismore difficult
than the noninvasive tumors. Therefore, the tumor re-
currence may be seen in a short period after operation.
Tumor invasion into surrounding tissues is a com-
plex phenomenon and characteristic of more aggres-
sive and oftenmalignant tumor behavior. The invasive
factors involve the heparinase, serine proteinases,
cathepsins, and matrix metalloproteinases (5).MMPs
are proteolytic enzymes that have the capability of
breaking down basement membrane and connective
tissue, and are important for tissue breakdown in the
process of tumor invasion (6, 7). Among these invasive
factors, MMP-2 andMMP-9 have been widely studied
in lung cancers, breast cancers and other malignant
neoplasms (8). Several studies examined the expres-
sion of MMPs in malignant gliomas (9-12). However,
the expression of MMP-2 andMMP-9 in the invasive
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pituitary adenomas showed different results in the
previous studies. Thismaybe related todifferentmeth-
ods, or different value of assessing the data.
The aim of this study was to determine whether
expression of MMP-2 and MMP-9 might play a role
in cavernous sinus invasion of pituitary adenomas.
The possible mechanisms was investigated in cavern-
ous sinus invasion of pituitary adenomas.
MATERIALS AND METHODS
Samples of pituitary adenomas were obtained from
54 patients who had undergone surgery from Oc-
tober 1984 to September 2001 at the KagawaMedical
University Hospital. Thirty-four patients were women
and 20weremen, with amean age of 49.9 years (range
18-76 years). There were 12 cases with cavernous in-
vasion (Fig. 1), and 42 cases without invasion. There
were 12 growth hormone (GH)-producing adenomas,
11 prolactin (PRL)-producing adenomas, 4 adrenocor-
ticotropic hormone (ACTH)-producing adenomas,
one thyroid stimulating hormone (TSH)-producing
adenomas, one follicle-stimulating hormone (FSH)
-producing adenomas, and 25 nonfunctioning (NF)
pituitary adenomas. Invasion to cavernous sinus space
of pituitary adenomas was defined on the basis of the
classification by Knops. Invasive and non-invasive ade-
noma are distinguished from each other by a medial
target, the intercarotid line, through the cross-sectional
centers (Fig.1) (13).
IMMUNOHISTOCHEMISTRY
MMP-2 and MMP-9 expression and proliferative
potential were examined immunohistochemically on
formalin-fixed, paraffin-embeddedsectionsusingmon-
oclonal antibodies (MAbs) against MMP-2 (Ab -2 ;
Fuji-chemistry, Japan), MMP-9 (Ab-2 ; Fuji-chemistry,
Japan) andMIB-1MAb(Immunotech,Marseille,France).
Six-micron sections were deparaffinized in xylene,
rehydrated through graded alcohols, and immersed
for 15 min in phosphate-buffered saline (PBS). For an-
tigen retrieval, the sections were microwaved in 0.01
M citrite buffer (pH 6.0) for 20 min. After microwave
pretreatment, the endogenous peroxidase activitywas
blocked with 3% hydrogen peroxidase in methanol
for 10 min, and nonspecific stainingwas then blocked
by 20-min incubation with normal horse serum. The
sections were then incubated overnight at 4℃ with
primary antibodies (MMP-2, ×100 ; MMP-9, ×100 ;
MIB-1, ×50) in a humidity chamber. The sections were
treated for 30 min with biotinylated horse secondary
Figure 1. MRI imaging of invasive pituitary adenomas. Non-invasive pituitary adenomas are disguished from invasive
adenomas by a medial tangent, the intercarotid line-through the cross-sectional centers-and a lateral tangent on the
intra and supracavernous internal carotid arteries. Case A ; The pituitary adenoma is huge but is classified in non-
invasive type. Case B and C ; The adenomas are not large but are considered as invasive type.
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antibody against mouse immunoglobulins (ABCElite,
Vector Lab., Burlingame, CA, USA) and for 30 min
with avidin-biotin complex (ABC Elite, Vector Lab.),
followed by 0.06 % diaminobenzidine (Sigma, MO,
USA) with 0.01% hydrogen peroxidase for 5min. The
slides were lightly counterstained with hematoxylin.
Controls were performed by omitting the primary
antibody.
A semi-quantitative assessment of the immuno-
histochemistry of MMP-2 andMMP-9 was employed
by grading the staining as (0) negative, (1)＜30%, (2)
30 -60%, (3) 60 -100% of tumor cells showing positive
staining. The intensity of the immunostainingwas also
graded as (0) negative, (1) weak, (2) moderate, and
(3) strong. The total immunohistochemical score was
determined as the sum of the frequency and intensity
scores for tumor cells (14). Twenty representative
fields were counted, and the immunohistochemistry
scores were determined by concordance among the
scores of two independent reviewers. The score was
divided into 0 -6 for each sample.
The MIB-1 LI was calculated as the percentage of
immunostained nuclei, excluding nuclei of vascular
components and hematogenous cells, by counting
approximately 200 tumor nuclei.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR) Analysis
RNA was extracted from the frozen tissue sample
by using ISOGEN regent (Nippon Gene, Toyama,
Japan). Briefly, 100 mg of pituitary adenomas tissue
was homogenized in 1 ml of ISOGEN. Subsequently,
0.2 ml of chloroform was added and themixwas cen-
trifuged. This separated the solution into an aqueous
phase containing RNA, an interphase containingDNA,
and an organic phase containing protein. The aqueous
layer was aspirated and added to 0.5ml of isopropanol
for RNA precipitation. Following this, the solution was
centrifuged and the pellet waswashedwith 70% ethanol
and centrifuged. After that, RNA was collected into
50µl of diethylpyrocarbonate (DEPC)-treated water.
RT-PCR was performed using a First-Strand cDNA
Synthesis Kit (AmershamPharmacia BiotechUKLim-
ited). Two microlitre of total RNA (2µg) was added
to 5.5µl of the RTmixture. After mixing, the samples
were incubated at 37℃ for 45min, 95℃ for 5min, and
4℃ for at least 5 min. 17.5 microlitre of PCR-mixture
containing 12.5µl primers and Taq DNA polymerase
(Amersham Pharmacia Biotech UK Limited) was
added to the RT products. Initial denaturation for 2
min at 94℃was followed by 30 cycles of 1min at 94℃,
1 min at 55℃, and 2 min at 72℃, and a final extension
for 6 min at 72℃. The PCR products were separated
on 2% agarose gels, and ethidium bromide-stained
bands were recorded byMupid-2R (Cosmo-Bio, Tokyo,
Japan). The primer sequences were as follows :
MMP-2 : forward primer : 5’primer : 5’-GCTGAT
ACTGACACTGGTACTG-3’, reverse primer : 5’-CAA
TCTTTTCTGGGAGCTC-3’.
MMP-9 : forward primer : 5’primer : 5’-AAGGAT
GGTCTACTGGCAC-3’, reverse primer : 5’-AGAGA
TTCTCACTGGGGC-3’(15).
β-actin : forward primer : 5’primer : 5’-ATCACCA
TTGGCAATGAGGG-3’, reverse primer : 5’-TTGAA
GGTAGTTTCGTGGAT-3’.
The results of percentage ofMMP-2mRNA/β-actin
mRNA and MMP-9 mRNA/β-actin mRNA were as-
sessed by NIH software using computer.
Statistical analysis
Student’s t-text was used to evaluate the relation-
ships among various parameters. The effect of various
parameters, i.e., tumor size, MMP-2 score, MMP-9
score, MIB-1 LI and percentage of MMP-2 mRNA/
β-actin mRNA andMMP-9mRNA/β-actinmRNAwas
assessed, using the STATVIEW for windows software
performed statistical analysis.
RESULTS
Immunohistochemistry findings
The cytoplasm and/or nuclear of tumor cells were
stained as brown color in pituitary adenomas (Fig. 2).
In this study, Forty-six cases (82 %) of 54 pituitary ade-
nomas were observed positive immunoreactivity,
whereas, staining intensity was variable. MMP-2 and
MMP-9 positive staining could be seen in all 12 cases
of invasive pituitary adenomas. TheMMP-2 score of
invasive pituitary adenoma (3.9±0.5) (mean±SE)were
significantly higher than those without invasion (2.3±
0.2) (p＜0.01). TheMMP-9 score of invasive pituitary
adenoma (4.1±0.4) were significantly higher than
those without invasion (2.6±0.2 ; p＜0.01) (Table 1).
We found that invasive pituitary adenomas were sig-
nificantly more likely to express MMP-2 andMMP-9
compared with noninvasive pituitary adenomas. The
MIB-1 LI tended to be higher in invasive pituitary ade-
nomas (1.2±0.4 %) than that (0.6±0.2 %) in noninva-
sive tumors, however, there was no significant differ-
ence (p=0.1528). There was no correlation between the
MMP-2 and MIB-1 LI (r=-0.05, p=0.72), MMP-9 and
MIB-1 LI (r=0.004, p=0.98). According to tumor size,
we divided the 54 pituitary adenomas into 4 groups
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(≦10 mm , ＞10 mm to ≦20 mm, ＞20 mm to ≦40
mm, and ＞40 mm), and compared the expression of
MMP-2, MMP-9, andMIB-1 LI in the different groups.
There were no significant differences among the 4
groups (Table 2). There are also no correlation in
MMP-2, andMMP-9 expression among ACTH, PRL,
or GH producing adenomas and NF pituitary adeno-
mas (Table 3).
mRNA Expression of MMPs
We examined MMP-2 and MMP-9 mRNA by RT-
PCR from 16 cases including 4 invasive and 12 non-
invasive pituitary adenomas. The expression ofMMP-
2 andMMP-9 mRNAwas also observed in the invasive
pituitary adenomas and noninvasive tumor (Fig. 3).
The percentage of MMP-2mRNA/β-actinmRNAwas
observed significantly higher in invasive pituitary ade-
nomas (68.2±15.3 %) than those without invasion
(21.8±8.2 % ; p＜0.05). The percentage of MMP-9
mRNA/β-actin mRNAwas observed significantly higher
in invasive pituitary adenomas (59.7±12.5%) than those
of noninvasive adenomas (33.3±5.4 % ; p＜0.05) (Fig. 4).
There are significant correlation betweenmRNA and
immunohistochemistry score in MMP-2 andMMP-9
(r=0.582, p＜0.05 ; r=0.669, p＜0.01) (Fig. 5).
Table 1. The score of MMP-2 and MMP-9 expression in
invasive and noninvasive pituitary adenomas
Group
No. of
patients
Age
Score
of MMP-2
Score
of MMP-9
MIB-1 LI
Invasion 12 52.7±3.6 3.9±0.5＊＊ 4.1±0.4＊＊ 1.2±0.4
Noninvasion 42 48.9±2.6 2.3±0.2 2.6±0.2 0.6±0.2
Patients age, score of MMP-2, MMP-9 expression and MIB-1
LI are expressed as means±SE.
＊＊ : P＜0.01 vs noninvasion group LI : labeling index.
Table 2. Correlation with the expression levels of MMP-2
and MMP-9 and the tumor size
Group
Tumor
size(mm)
No. of
patients
Age
Score
of MMP-2
Score
of MMP-9
P value
1 ≦10 10 31.6±4.5 2.1±0.5 2.1±0.5 NS
2 ＞10 to ≦20 20 52.2±3.2 3.0±0.4 3.0±0.3 NS
3 ＞20 to ≦40 21 56.3±2.9 2.7±0.4 3.2±0.4 NS
4 ＞40 3 48.7±6.7 2.3±0.3 3.0±0.6 NS
Patients age, and score ofMMP-2,MMP-9 expression are expressed
as means±SE.
NS : not significant
Table 3. Correlation with the expression ofMMP-2 andMMP-9
and the hormone secreting pituitary adenomas
Group
No. of
patients
Score
of MMP-2
Score
of MMP-9
P value
ACTH 4 2.0±0.7 2.5±0.9 NS
GH 12 2.8±0.5 3.1±0.4 NS
PRL 11 2.7±0.5 2.9±0.6 NS
NF 25 2.7±0.3 3.0±0.3 NS
The score of MMP-2, MMP-9 expression are expressed as
means±SE.
NS : not significant. NF : nonfunction
Figure 2. Immunohistochemical staining of MMP-2 (A) and MMP-9 (B) in invasive pituitary adenomas. Photograph showing
cytoplasmic and/or nuclear immunoreactivity of the tumor cells. Negative control for MMP-2 (C) andMMP-9 (D) (magnification
×400)
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Figure 4. The graph showed the significant differences of MMPs mRNA expression between in the invasive cases and in
the noninvasive cases (＊p＜0.05). (A) MMP-2. (B) MMP-9.
Figure 5. The graph showed that there are significant correlation between mRNA and immunohistochemistry score in
MMP-2 and MMP-9. (A) MMP-2 and MMP-2 mRNA (r=0.582, p＜0.05) ; (B) MMP-9 and MMP-9 mRNA (r=0.669, p＜0.01)
Figure 3. Expression of MMP-2 (A), MMP-9 (B) mRNA by RT-PCR withβ-actin serving as a control for equal loading in pituitary
adenomas. (A) Positive bands are oberserved in the invasive cases (case 3, 8, 12, and 14). (B) Positive bands are found in the
invasive cases (case 3, 8, 12, and 14). The levels of MMP-2 were quantitated by using NIH image (version 1.61).
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DISCUSSION
MMPs are a family of zinc-dependent endopeptidases
that regarded as promoting of invasion andmetastasis
(16). The family includes five subclasses : collagenases,
gelatinases, stromelysins,metalloelastase andmembrane-
type metalloproteinases.MMPs have been implicated
in various physiological and tissue morphogenesis
as well as tumor cell invasion andmetastasis (17). The
MMP-2 and MMP-9 are the common studied gela-
tinases and can degrade the basement-membrane type
Ⅳ collagen. Tumor cell invasion utilizes numerous
proteases in vitro , of which the predominant ones
may be gelatinase-A and -B (MMP-2 andMMP-9 re-
spectively) (18). Nakada, et al. (19) demonstrated that
the production levels of MMP-2 are significant higher
in glioblastomas multiforme than in other grades of
astrocytic tumors. Several studies indicated that there
presented significant correlation between theMMP-2
and MMP-9 expression and invasion in themalignant
tumors (20-25).
The majority of pituitary adenomas are benign and
do not metastasize. However, it always doubted the
neurosurgeons that parts of pituitary adenomas are
locally invasive and more than 20% cases recur (26 -
28). The invasive behavior of pituitary adenomas is
poorly understood. In present study, we evaluated the
expression of MMP-2 and MMP-9 by immunohis-
tochemistry and MMP-2 and MMP-9 mRNA level
by RT-PCR assay in pituitary adenomas. We found
that invasive pituitary adenomas have a significantly
higher expression of MMP-2 and MMP-9 protein,
and mRNA than noninvasive tumors. Turnere, et al. (9)
found that invasive macroprolactinomas were signifi-
cantly more like to expressMMP-9 than noninvasive
tumor. Kawamoto et al. described that the incidence
of tumor cells secreting MMP-9 was significantly
higher in invasive pituitary adenomas than in nonin-
vasive ones (11). Pereta, et al. found the high expres-
sion of MMPs and low levels of TIMP-1 in pituitary
adenomas, and the active form of the MMP-2 was
found in some pituitary tumors (29). They also showed
that high level of MMP activity could be to contribute
the regulation of proliferation and hormone secretion
in pituitary adenomas (28). We failed to find the sig-
nificant difference of MMPs expression among the
hormone (GH, PRL, and ACTH) secreting adenoma
and NF pituitary adenomas. Our data suggest that
proteases, MMP-2/-9, may play a role in tumor inva-
siveness of pituitary adenomas and did not correlate
with hormone secreting activity.
A number of studies have been widely considered
that Ki-67 LI is the best means to evaluate cell prolif-
eration in clinical practice. It is also considered auseful
tool for assessing the recurrence of the tumor (30, 31).
We have previously shown that no correlation between
MMP-2/-9 expression and the Ki67 LI expression in
gliomas (32). Mastronardi’s study showed that the
Ki-67 LI was a useful marker in determining the
invasive behaviour of pituitary adenomas, andhis results
also seem to exclude significant correlations between
MIB 1 LI and tumor size of pituitary adenomas (33,
34). For the first time, we have demonstrated that there
was no difference betweenMIB1 LI of invasive pitui-
tary adenomas and that of noninvasive adenomas,
and no correlations were foundbetween the expression
of MMP-2/-9 and MIB-1 LI, MMP-2/-9 expression
and tumor size. The present data suggested that the
expression of MMP-2 and MMP-9 were the index
markers of tumor invasion, whereas the expression
of MMP-2 and MMP-9 had no correlation with the
proliferation of the pituitary adenomas. Some re-
searcher (6-9) found that the expression of MMP-9
was relatedwith the invasiveness in pituitary adenomas,
however few authors examined theMMP-2 expression
in pituitary adenomas. Our study demonstrated the
correlation between the expression ofMMP-2, as well
as MMP-9, and cavernous invasion in pituitary ade-
nomas. We also found that some of the tumors, in spite
of their small size, invade the cavernous sinus or the
surrounding area, whereas some huge pituitary ade-
nomas did not invade the surrounding structures.
Our data may explain this phenomenon. Turner’s
study the adenomas removed when they recurred
were more likely to express MMPs (9). On the other
hand, Knappe et al. found no differences in expression
of MMP9 in recurrent adenomas (35). Sampling of
tumor tissue is done to the opening in the intrasellar
parts of the tumor during transsphenoidal surgery
and the areas of lateral invasion are cleaned by the
suction rather than excision. Therefore, we could not
investigate differences of expression of MMP-2/-9
in distinct areas of possible dural invasiveness, nor
compare them with central intrasellar areas of the
tumors.
Although there may be many biochemical mecha-
nisms about the invasion of tumors, the present data
can partially explain the invasive behavior of pituitary
adenomas. Our study indicated that the expression of
MMP-2 andMMP-9 had a value to assess the invasion
in pituitary adenomas, while theMIB-1 LI was not the
index of tumor invasion.
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